Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.radonc.2020.05.032

Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic

Lucas C. Mendez & Eric Leung et al. · 2020-05-28

Cervical cancer is a deadly disease and the COVID-19 pandemic has the potential to further impact its lethality. Hypofractionated radiotherapy could mitigate this impact, however robust data in cervical cancer setting still is lacking. Information provided here could help institutions in reducing radiotherapy fractions for cervical cancer patients.

Links

DOI PubMed

Journal

Radiotherapy and Oncology

Authors

Lucas C. Mendez, Hamid Raziee, Melanie Davidson, Vikram Velker, David D'Souza, Elizabeth Barnes, Eric Leung